Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , appears to represent a promising step forward for weight loss . Early patient trials have shown considerable losses https://explorebookmarks.com/story21327585/the-retatrutide-peptide-the-breakthrough-in-body-management